SG11201609365UA - Compounds for treating brain cancer - Google Patents

Compounds for treating brain cancer

Info

Publication number
SG11201609365UA
SG11201609365UA SG11201609365UA SG11201609365UA SG11201609365UA SG 11201609365U A SG11201609365U A SG 11201609365UA SG 11201609365U A SG11201609365U A SG 11201609365UA SG 11201609365U A SG11201609365U A SG 11201609365UA SG 11201609365U A SG11201609365U A SG 11201609365UA
Authority
SG
Singapore
Prior art keywords
compounds
brain cancer
treating brain
treating
cancer
Prior art date
Application number
SG11201609365UA
Inventor
Thomas Mehrling
Claudio Festuccia
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of SG11201609365UA publication Critical patent/SG11201609365UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11201609365UA 2014-05-28 2015-03-26 Compounds for treating brain cancer SG11201609365UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1409471.8A GB201409471D0 (en) 2014-05-28 2014-05-28 Pharmaceutical composition
PCT/EP2015/056667 WO2015180865A1 (en) 2014-05-28 2015-03-26 Compounds for treating brain cancer

Publications (1)

Publication Number Publication Date
SG11201609365UA true SG11201609365UA (en) 2016-12-29

Family

ID=51177574

Family Applications (4)

Application Number Title Priority Date Filing Date
SG11201609365UA SG11201609365UA (en) 2014-05-28 2015-03-26 Compounds for treating brain cancer
SG10201810397SA SG10201810397SA (en) 2014-05-28 2015-03-26 Compounds for treating brain cancer
SG10201810401RA SG10201810401RA (en) 2014-05-28 2015-05-26 Pharmaceutical combinations for treating cancer
SG11201609360WA SG11201609360WA (en) 2014-05-28 2015-05-26 Pharmaceutical combinations for treating cancer

Family Applications After (3)

Application Number Title Priority Date Filing Date
SG10201810397SA SG10201810397SA (en) 2014-05-28 2015-03-26 Compounds for treating brain cancer
SG10201810401RA SG10201810401RA (en) 2014-05-28 2015-05-26 Pharmaceutical combinations for treating cancer
SG11201609360WA SG11201609360WA (en) 2014-05-28 2015-05-26 Pharmaceutical combinations for treating cancer

Country Status (22)

Country Link
US (7) US11419853B2 (en)
EP (4) EP3148529B1 (en)
JP (3) JP6553092B2 (en)
KR (2) KR102383794B1 (en)
CN (3) CN106659712A (en)
AU (2) AU2015266342B2 (en)
BR (2) BR112016027048B1 (en)
CA (2) CA2950374C (en)
DK (1) DK3148529T3 (en)
EA (2) EA037057B1 (en)
ES (2) ES2897727T3 (en)
GB (1) GB201409471D0 (en)
IL (2) IL249231B (en)
MX (2) MX2016015436A (en)
NZ (1) NZ725595A (en)
PH (2) PH12016502354A1 (en)
PT (1) PT3148529T (en)
SG (4) SG11201609365UA (en)
TW (1) TWI724990B (en)
UA (2) UA121311C2 (en)
WO (2) WO2015180865A1 (en)
ZA (1) ZA201607384B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR092790A1 (en) 2012-02-01 2015-05-06 Euro Celtique Sa BENCIMIDAZOLIC DERIVATIVES OF HYDROXAMIC ACID
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201601773D0 (en) 2016-02-01 2016-03-16 Renishaw Plc Method
TWI794171B (en) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-l1 inhibitors
TWI808055B (en) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-1 inhibitors
AU2016426574B2 (en) 2016-10-11 2023-07-13 Euro-Celtique S.A. Hodgkin lymphoma therapy
TWI651088B (en) 2017-03-23 2019-02-21 國立東華大學 Scalarane sesquiterpenoids, pharmaceutical compositions, topoisomerase II and Hsp90 inhibitors for treating cancer, use thereof and preparation method thereof
GB201709405D0 (en) * 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
EP3694878A1 (en) * 2017-09-14 2020-08-19 GlaxoSmithKline Intellectual Property Development Limited Combination treatment for cancer
AU2019402158A1 (en) * 2018-12-18 2021-06-10 Mundipharma International Corporation Limited Compounds for treating lymphoma or a T-cell malignant disease
CN112023022A (en) * 2020-10-20 2020-12-04 澳门大学 New application of carfilzomib in preparation of drug for treating drug-resistant tumor
JP2022156070A (en) 2021-03-31 2022-10-14 株式会社小糸製作所 image projection device

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE34727C (en) Ch. H. TH. HAVEMANN in Paris, 16 rue Bleue Process for the direct extraction of metallic lead
DD34727A1 (en) 1963-12-21 1964-12-28 Dietrich Krebs A process for the preparation of 1-position substituted [5-bis (chloroethyl) amino-benzimidazolyl (2)] - alkanecarboxylic acids
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
KR0166088B1 (en) 1990-01-23 1999-01-15 . Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
GB9126209D0 (en) 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5882941A (en) 1994-05-04 1999-03-16 Massachusette Institute Of Technology Programmable genotoxic agents and uses therefor
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
AU750207B2 (en) 1997-06-13 2002-07-11 Cydex Pharmaceuticals, Inc. Polar drug or prodrug compositions with extended shelf-life storage and a method of making thereof
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6214852B1 (en) 1998-10-21 2001-04-10 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6392053B2 (en) 1999-12-15 2002-05-21 Bristol-Myers Squibb Company Process for preparing arylacetylaminothiazoles
WO2002004009A2 (en) 2000-07-12 2002-01-17 Immunex Corporation Method for treating cancer using an interleukin- 4 antagonist
PE20020354A1 (en) 2000-09-01 2002-06-12 Novartis Ag HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS
EP1598067B1 (en) 2000-09-29 2009-05-06 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage for the treatment of malaria
AU2002243231A1 (en) 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases
CN1764648A (en) 2003-01-13 2006-04-26 安斯泰来制药有限公司 hydroxamid acid derivatives as histone deacetylase (HDAC) inhibitors
JP4790594B2 (en) 2003-02-25 2011-10-12 トポターゲット ユーケー リミテッド Hydroxamic acid compounds containing bicyclic heteroaryl groups as HDAC inhibitors
JP2007501775A (en) 2003-08-07 2007-02-01 ノバルティス アクチエンゲゼルシャフト Histone deacetylase inhibitors as immunosuppressants
JP4993374B2 (en) 2004-04-05 2012-08-08 メルク エイチディーエーシー リサーチ エルエルシー Histone deacetylase inhibitor prodrug
WO2007134169A2 (en) 2006-05-10 2007-11-22 Nuada, Llc Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
JP5108750B2 (en) 2005-05-13 2012-12-26 トポターゲット ユーケー リミテッド Pharmaceutical formulation of HDAC inhibitor
UA95310C2 (en) 2006-10-20 2011-07-25 Айкос Корпорейшен Composition containing chkl inhibitor and cyclodextrin for the treatment of cancer
GB0621160D0 (en) 2006-10-24 2006-12-06 Imp College Innovations Ltd Compounds and uses thereof
CN101784268B (en) 2006-11-20 2013-06-19 赛福伦公司 Method of radio-sensitizing tumors using a radio-sensitizing agent
JP2010512407A (en) * 2006-12-11 2010-04-22 ジェネンテック インコーポレイテッド Compositions and methods for treating neoplasms
CN101084876A (en) 2007-07-11 2007-12-12 济南康泉医药科技有限公司 Anti-cancer composition containing bendamustine
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
US20090131367A1 (en) 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
WO2009100045A1 (en) 2008-02-04 2009-08-13 Translational Genomics Research Institute Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives
CA2735899A1 (en) 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
EP2346836B1 (en) 2008-10-08 2018-03-07 Cephalon, Inc. Processes for the preparation of bendamustine
WO2010075542A1 (en) 2008-12-23 2010-07-01 Curis, Inc. Cdk inhibitors
CA2750413C (en) * 2009-01-23 2016-06-21 Northlake Biosciences Llc Hydroxamic acid derivatives
CA2753641C (en) 2009-02-25 2014-09-16 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
WO2011017448A1 (en) 2009-08-05 2011-02-10 The Trustees Of The University Of Pennsylvania Use of histone deacetylase inhibitors for treatment of autoimmune diseases
CN101928234B (en) 2010-01-15 2012-12-12 北京欧凯纳斯科技有限公司 6/7-(hetero)aryl-N-hydroxyl hexanamide/heptamide compounds and method for preparing same
WO2011127948A1 (en) 2010-04-16 2011-10-20 Cellact Pharma Gmbh Analogues of etoposide for the treatment of tumours
ES2602475T3 (en) 2010-04-15 2017-02-21 Tracon Pharmaceuticals, Inc. Enhancement of anticancer activity by combination therapy with BER inhibitors
JO3659B1 (en) 2010-06-02 2020-08-27 Astellas Deutschland Gmbh Oral dosage forms of bendamustine and therapeutic use thereof
US8748470B2 (en) 2011-03-17 2014-06-10 The University Of Chicago Methods for treating ovarian cancer by inhibiting fatty acid binding proteins
US9492423B2 (en) 2011-09-13 2016-11-15 Pharmacyclics Llc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
CN102993102B (en) 2011-09-16 2016-08-24 杭州民生药业有限公司 The synthetic method of [1-methyl-2-(hydroxamic acid base in 7 '-heptan)-5-N, N-bis-(2 '-chloroethyl)]-1H-benzimidazole
ME03088B (en) 2011-09-18 2019-01-20 Euro Celtique Sa Pharmaceutical composition comprising an hdac inhibitor and a cyclopolysaccharide
MX342746B (en) 2011-09-28 2016-10-11 Euro-Celtique S A * Nitrogen mustard derivatives.
AR092790A1 (en) * 2012-02-01 2015-05-06 Euro Celtique Sa BENCIMIDAZOLIC DERIVATIVES OF HYDROXAMIC ACID
WO2015085289A1 (en) 2013-12-06 2015-06-11 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
NZ630314A (en) 2014-02-18 2016-03-31 Celgene Corp Combination therapy for hematological malignancies
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
JP2017537164A (en) 2014-12-05 2017-12-14 ユニヴァーシティ・オブ・モデナ・アンド・レッジョ・エミリア Combination of histone deacetylase inhibitor and bendamustine for the treatment of lymphoma
US20180311215A1 (en) 2015-10-20 2018-11-01 Hangzhou TINO Pharma Co., Ltd. Pharmaceutical composition and preparation method therefor
AU2016426574B2 (en) 2016-10-11 2023-07-13 Euro-Celtique S.A. Hodgkin lymphoma therapy
US20180098969A1 (en) 2016-10-11 2018-04-12 Purdue Pharmaceutical Products L.P. Hodgkin lymphoma therapy
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
AU2019402158A1 (en) 2018-12-18 2021-06-10 Mundipharma International Corporation Limited Compounds for treating lymphoma or a T-cell malignant disease

Also Published As

Publication number Publication date
CA2950338C (en) 2024-01-16
EA035658B1 (en) 2020-07-23
ES2949222T3 (en) 2023-09-26
EP3148529A1 (en) 2017-04-05
CN111467339A (en) 2020-07-31
EA201692480A1 (en) 2017-04-28
IL249231B (en) 2022-09-01
BR112016027041A8 (en) 2021-07-20
EA037057B1 (en) 2021-01-29
JP6553092B2 (en) 2019-07-31
JP7274450B2 (en) 2023-05-16
EP3148536C0 (en) 2023-06-28
SG11201609360WA (en) 2016-12-29
EP3148536B1 (en) 2023-06-28
EP3998068A1 (en) 2022-05-18
CN106659712A (en) 2017-05-10
BR112016027048B1 (en) 2023-01-03
EP3957307A1 (en) 2022-02-23
IL249229B (en) 2020-07-30
AU2015266052A1 (en) 2016-11-10
ZA201607384B (en) 2021-06-30
US20180369204A1 (en) 2018-12-27
UA122207C2 (en) 2020-10-12
PT3148529T (en) 2021-11-17
CN106470696A (en) 2017-03-01
GB201409471D0 (en) 2014-07-09
US20170151218A1 (en) 2017-06-01
US20230241033A1 (en) 2023-08-03
PH12016502355A1 (en) 2017-02-13
KR102451701B1 (en) 2022-10-06
CA2950338A1 (en) 2015-12-03
IL249231A0 (en) 2017-02-28
WO2015180865A1 (en) 2015-12-03
US10406138B2 (en) 2019-09-10
JP2017518291A (en) 2017-07-06
TW201625240A (en) 2016-07-16
JP2021059579A (en) 2021-04-15
SG10201810401RA (en) 2018-12-28
US20230049350A1 (en) 2023-02-16
TWI724990B (en) 2021-04-21
ES2897727T3 (en) 2022-03-02
US20170189382A1 (en) 2017-07-06
BR112016027041B1 (en) 2023-03-21
NZ725595A (en) 2023-03-31
AU2015266342B2 (en) 2020-07-02
EP3148529B1 (en) 2021-10-20
AU2015266052B2 (en) 2020-07-09
KR20170012372A (en) 2017-02-02
PH12016502354A1 (en) 2017-02-13
KR20170005106A (en) 2017-01-11
MX2016015436A (en) 2017-07-04
JP2017516781A (en) 2017-06-22
EP3148536A1 (en) 2017-04-05
PH12016502355B1 (en) 2017-02-13
AU2015266342A1 (en) 2016-11-10
CA2950374C (en) 2023-10-03
US11559516B2 (en) 2023-01-24
BR112016027048A8 (en) 2021-07-20
US20210346351A1 (en) 2021-11-11
IL249229A0 (en) 2017-02-28
CA2950374A1 (en) 2015-12-03
SG10201810397SA (en) 2018-12-28
MX2016015434A (en) 2017-06-23
UA121311C2 (en) 2020-05-12
US20190343807A1 (en) 2019-11-14
BR112016027041A2 (en) 2017-08-15
BR112016027048A2 (en) 2017-08-15
WO2015181156A1 (en) 2015-12-03
DK3148529T3 (en) 2021-12-13
EA201692472A1 (en) 2017-05-31
CN106470696B (en) 2021-04-27
KR102383794B1 (en) 2022-04-06
US11419853B2 (en) 2022-08-23

Similar Documents

Publication Publication Date Title
HK1251407A1 (en) Methods for treating cancer
HK1247202A1 (en) Compounds for the treatment of cancer
IL304252A (en) Method for treating cancer
IL249229B (en) Compounds for treating brain cancer
IL289947A (en) Method for treating cancer
HUE053654T2 (en) Combinations of fgfr- and cmet-inhibitors for the treatment of cancer
IL285077A (en) Compounds for treatment of cancer
SG10201801562PA (en) Combination method for treatment of cancer
HK1254258A1 (en) Methods for treating cancer using apilimod
SG11201610551TA (en) Combinations for treating cancers
HK1250944A1 (en) Methods for treating cancer
HK1248135A1 (en) Combination method for treating cancer
HK1250942A1 (en) Methods for treating cancer
IL246558A0 (en) Novel methods for treating cancer
HK1250943A1 (en) Methods for treating cancer
HK1259615A1 (en) Glutamine-high z element compounds for treating cancer
GB201420348D0 (en) Compounds for treating neurodegenerative diseases
HK1256371A1 (en) Methods for treating tumours
ZA201704589B (en) Compounds for the treatment of cancer
AU2014904697A0 (en) Compounds for treating cancer